Delving into the Latest Updates on BGP-15 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

Mechanism

HSP stimulants(Heat-shock protein stimulants), PARP inhibitors(Poly (ADP-Ribose) polymerase inhibitors), Insulin sensitizers

Therapeutic Areas

Nervous System DiseasesCongenital DisordersEndocrinology and Metabolic Disease+ [2]

Active Indication

Diabetes Mellitus, Type 2Muscular Dystrophy, Duchenne

Inactive Indication

Beta Ketothiolase DeficiencyChemotherapy-induced damageCOVID-19+ [3]

Originator Organization

N-Gene

Active Organization

N-Gene

Inactive Organization

N-Gene Research Laboratories, Inc.

Allos Therapeutics, Inc.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC14H22N4O2

InChIKeyMVLOQULXIYSERZ-UHFFFAOYSA-N

CAS Registry66611-38-9

View All Structures (2)

This is a safety and dose finding efficacy study to evaluate the effects of BGP-15 over the dose range of 100 mg/day to 400 mg/day. Doses are applied once or twice a day for 13 weeks as add-on therapy to the combination of metformin and sulfonylurea treatment or metformin alone in patients with Type 2 Diabetes Mellitus.

Start Date01 Oct 2010

Sponsor / Collaborator

N-Gene Research Laboratories, Inc.

[+6]

100 Clinical Results associated with BGP-15

Login to view more data

100 Translational Medicine associated with BGP-15

Login to view more data

100 Patents (Medical) associated with BGP-15

Login to view more data

79

Literatures (Medical) associated with BGP-15

01 Dec 2024·F&S Science

Mitochondrial activator BGP-15 protects sperm quality against oxidative damage and improves embryo developmental competence

Article

Author: Campugan, Carl A ; Febbraio, Mark A ; McPherson, Nicole O ; Rose, Ryan D ; Kennedy, David T ; Barry, Michael ; Gonzalez, Macarena B ; Connaughton, Haley S ; Robker, Rebecca L ; Winstanley, Yasmyn E

OBJECTIVETo study the efficacy of mitochondrial activator BGP-15 to preserve sperm quality and competence against cellular damage.DESIGNSpermatozoa from mice or humans were treated in vitro with BGP-15, and sperm quality markers were assessed. Spermatozoa from young (8-12 weeks old) or reproductively old (>14 months old) mice were treated with BGP-15 for 1 hour and assessed for sperm quality and preimplantation embryo development after in vitro fertilization. The safety of BGP-15 on offspring outcomes was assessed through embryo transfers. In parallel studies, spermatozoa from healthy (not infertile) men were incubated in hydrogen peroxide, to induce oxidative stress, plus increasing doses of BGP-15, and sperm quality was evaluated. Spermatozoa from patients undergoing assisted reproductive technology (ART) treatment were incubated in the optimized dose of BGP-15 for 30 minutes, and sperm quality was assessed.SUBJECTS AND ANIMALSC57BL/6 mice (N = 4-15 per group) for sperm quality and embryo development. CBAF1 mice (n = 6 per group) produced embryos for transfer. Human spermatozoa were from men with no infertility diagnosis (n = 14-20) or men undergoing ART (n = 33) at a local fertility clinic.EXPOSUREMouse spermatozoa were treated with 10-μM BGP-15. Human spermatozoa were treated with BGP-15 at doses from 1 to 100 μM.MAIN OUTCOME MEASURESSperm quality measures (mouse and human) included motility, mitochondrial membrane potential (JC-1 dye), deoxyribonucleic acid (DNA) fragmentation ("HALO" assay), and DNA oxidation (8-oxoguanine immunodetection). Mouse embryo and offspring measures included on-time development after in vitro fertilization, morphokinetic analysis, and blastocyst inner cell mass and trophectoderm cell number, and growth and development from birth to 21 days postnatally.RESULTSBGP-15 increased sperm motility and mitochondrial membrane potential and decreased DNA oxidation in old mice. BGP-15 improved on-time development of 2-cell and blastocyst embryos and increased the inner cell mass blastomere number. Embryos from BGP-15-treated mouse spermatozoa produced normal offspring. In human spermatozoa subjected to in vitro oxidative stress, BGP-15 increased motility by 45% and prevented DNA fragmentation (by 45%) and oxidative damage (by 60%). In spermatozoa from men attending a fertility clinic, BGP-15 increased motility by 12% and reduced both DNA oxidation and fragmentation by >20%.CONCLUSIONBGP-15 protects sperm against cellular damage and has the potential to improve ART outcomes.

01 Aug 2024·Brain, Behavior, and Immunity

Response to comment on: BGP-15 alleviates LPS-induced depression-like behavior by promoting mitophagy

Letter

Author: Liu, Qian ; Liu, Gong-Ping

A review.In this investigation, we discovered that BGP-15 can improve depressive-like behaviors (DLB) in mice by promoting PINK1/Parkin-dependent mitophagy, but the mechanism is not clear.In vitro studies revealed that BGP-15 interacts with mitochondrial proteins or lipids.It is hypothesized that the mechanism by which BGP-15 improves mitophagy may involve its mitochondrial targeting, warranting further investigation.

01 Aug 2024·Brain, Behavior, and Immunity

Commentary on the Article “BGP-15 alleviates LPS-induced depression-like behavior by promoting mitophagy”

Article

Author: Chen, Haiyang ; Ren, Lu ; Shi, Liuqing

A polemic in response to Liu et al., 2024 (Brain Behav. Immun. 119, 648-664)is given.Liu et al. described potential role of BGP-15 as a neuroprotective agent in enhancing mitophagy and suppressing the activation of the NLRP3 inflammasome offers fresh perspective for the treatment of depression.The author after a thorough anal. of the study raised few queries and suggestions as follows:.While the paper mentions that BGP-15 acts through the PINK1/Parkin-dependent mitophagy pathway, the specific mol. mechanisms by which BGP-15 influences this pathway are not elaborated. Could future research provide more details on the interaction between BGP-15 and proteins involved in mitophagy.Given that BGP-15 has shown good tolerability in other clin. trials, have the authors considered applying it to clin. studies involving patients with depression The outcomes of such studies could significantly impact clin. practice.The study utilized male mice, but it is well-documented that gender differences exist in the prevalence and presentation of depression. Will future studies consider including female mice to assess the impact of gender on the effects of BGP-15.Besides mitophagy and the NLRP3 inflammasome mentioned in the paper, are there other biomarkers or pathways that might be associated with the antidepressant effects of BGP-15.Author impressed by the depth and quality of this research and look forward to the authors' perspectives on the above issues and believe that further research and discussion will enable us to fully understand the potential of BGP-15 in the treatment of depression.

100 Deals associated with BGP-15

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 2	-	N-Gene	-
Muscular Dystrophy, Duchenne	Phase 2	-	N-Gene	-
Beta Ketothiolase Deficiency	Phase 1	HU	N-Gene Research Laboratories, Inc.	01 Oct 2010
Beta Ketothiolase Deficiency	Phase 1	US	N-Gene Research Laboratories, Inc.	01 Oct 2010
Beta Ketothiolase Deficiency	Phase 1	DE	N-Gene Research Laboratories, Inc.	01 Oct 2010
Chemotherapy-induced damage	Phase 1	HU	N-Gene Research Laboratories, Inc.	-
Reperfusion Injury	Phase 1	HU	-	-
COVID-19	Preclinical	HU	-	26 Mar 2021
Tachycardia, Sinus	Preclinical	HU	-	30 Sep 2020
Insulin Resistance	Preclinical	HU	N-Gene Research Laboratories, Inc.	04 Apr 2006